Ocuphire Pharma Investor Day Presentation Deck

RM 51 MIRA-2: Phase 3 RM Trial Met Primary Endpoint 49% of Patients Returned to ≤ 0.2mm of Baseline at 90 Minutes Percent of Subjects (%) 100% 80% 60% 40% 20% 0% MIRA-2 Phase 3 Trial Nyxol Reduced More Subjects to Baseline Pupil Diameter (PD) at Every Timepoint Placebo n=91 Nyxol n=94 3% 1% 0.5 2% Study Eye Percent of Subjects Returning to ≤ 0.2 mm of Baseline PD p<0.0001 28% 1 7% p<0.0001 49% 1.5 11% p<0.0001 59% 2 18% Time Post-Treatment with Nyxol/Placebo (Hours) Source: MIRA-2 Trial Table 14.1.2.1, mITT Population (same as Safety Population) *Data includes three of the most common mydriatics used in practice (Phenylephrine, Tropicamide, Paremyd) p<0.0001 80% 3 30% p<0.0001 82% 4 45% p<0.0001 90% CO 6 Ocuphire PHARMA

View entire presentation